Table 1.
Summary details and relevant characteristics of the studies
| STUDY | N (N males / N females) | Age Mean (SD) years | Type 2 diabetes cases/controls | Fasting glucose Mean (SD) mmol/l | 2-hr OGTT Mean (SD) mmol/l | Matsuda ISI Mean (SD) mg/dl, mU/l | Insulinogenic index Mean (SD) pmol/mmol | Disposition index Mean (SD) | BMI Mean (SD) kg/m2 | Height Mean (SD) cm | Genotyping |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Avon Longitudinal Study of Parents and Children study (ALSPAC) data(6) | 6,597 (0 / 6,597) | 28.1 (4.8) | NA | NA | NA | NA | NA | NA | 22.9 (3.8) | NA | Fluorescence based competitive allele-specific assay (KASPar) at LGC Genomics (Hoddesdon, UK) |
| Genetics of Diabetes Audit and Research Tayside Study (GoDARTS)(12) | 13,512 (7,078 / 6,434) | 61.1 (10.6) | 6,145/5,045 | 4.9 (0.7) | NA | NA | NA | NA | 29.3 (5.8) | 167.9 (9.7) | Fluorescence based competitive allele-specific assay (KASPar) at LGC Genomics (Hoddesdon, UK) |
| Metabolic Syndrome in Men (METSIM)(5) | 8,102 (8,120/0) | 57.2 (7.1) | 1,602/6,500 | 5.7 (0.5) | 6.1 (1.7) | 6.9 (4.2) | 131.3 (220.3) | 739.2 (1566) | 26.8 (3.8) | 176.0 (6.4) | TaqMan Allelic Discrimination Assays (Applied Biosystems) |
| Relationship between Insulin Sensitivity and Cardiovascular disease (RISC)(13) | 1,285 (574 / 711) | 43.8 (8.3) | NA | 5.1 (0.6) | 5.7 (1.5) | 11.6 (6.1) | 96.9 (82.6) | 996.7 (990) | 25.5 (4.1) | 170.7 (9.4) | Fluorescence based competitive allele-specific assay (KASPar) at LGC Genomics (Hoddesdon, UK) |